Androgen Replacement as Treatment for Hormone Refractory Prostate Cancer
Abstract
This grant funded planning activities for initiation of a randomized phase II trial to study androgen replacement in early phase hormone refractory prostate cancer. A grant was completed and submitted to the DOD. A clinical protocol was completed and submitted to the lRB. All regulatory and collaborative agreements were completed except for finalization of drug delivery process with the pharmaceutical collaborator when it was announced that the clinical trial grant was not funded.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2005
- Accession Number
- ADA442980
Entities
People
- Walter M. Stadler
Organizations
- University of Chicago